Related Experiment Videos
Spironolactone-induced agranulocytosis
A M Whitling1, P E Pérgola, J L Sang
1Clinical Pharmacy Programs, College of Pharmacy, University of Texas at Austin, USA.
The Annals of Pharmacotherapy
|May 1, 1997
Summary
Spironolactone can cause agranulocytosis, a serious condition where the body lacks infection-fighting white blood cells. Early detection and stopping the drug are crucial for patient recovery.
Area of Science:
- Pharmacology
- Hematology
- Hepatology
Background:
- Spironolactone is a medication used for conditions like heart failure and high blood pressure.
- Drug-induced agranulocytosis is a rare but severe adverse effect.
- Cryptogenic liver disease presents unique challenges in medication management.
Observation:
- A case of agranulocytosis was observed in a patient with cryptogenic cirrhosis treated with spironolactone.
- Leukocyte and absolute neutrophil counts dropped significantly after spironolactone initiation.
- Bone marrow biopsies indicated a toxic effect of spironolactone on myeloid precursors.
Findings:
- Spironolactone was identified as the cause of agranulocytosis in this patient.
- Agranulocytosis resolved within five days of discontinuing spironolactone.
- The incidence of drug-induced agranulocytosis is approximately 6.2 cases per million persons annually.
Implications:
- Patients with risk factors such as age, hepatic/renal impairment, or concurrent medications may be at higher risk.
- Close monitoring for agranulocytosis is recommended in patients taking spironolactone.
- Early recognition and drug cessation can significantly improve patient outcomes.